Reviewing Nutriband (NTRB) & The Competition

Nutriband (NASDAQ:NTRB) is one of 896 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Nutriband to related companies based on the strength of its valuation, earnings, risk, dividends, institutional ownership, analyst recommendations and profitability.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Nutriband and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nutriband	1	1	0	0	1.50
Nutriband Competitors	7782	13874	25765	1035	2.41

As a group, “Pharmaceuticals” companies have a potential upside of 25.86%. Given Nutriband’s rivals stronger consensus rating and higher probable upside, analysts clearly believe Nutriband has less favorable growth aspects than its rivals.

Profitability

This table compares Nutriband and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nutriband	-430.35%	-109.07%	-95.54%
Nutriband Competitors	-2,381.29%	-218.58%	-15.77%

Institutional and Insider Ownership

19.7% of Nutriband shares are held by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 52.2% of Nutriband shares are held by company insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Nutriband and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Nutriband	$1.62 million	-$8.23 million	-10.36
Nutriband Competitors	$5.42 billion	$3.22 billion	550.74

Nutriband’s rivals have higher revenue and earnings than Nutriband. Nutriband is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Nutriband has a beta of 2.17, suggesting that its stock price is 117% more volatile than the S&P 500. Comparatively, Nutriband’s rivals have a beta of -3.66, suggesting that their average stock price is 466% less volatile than the S&P 500.

Summary

Nutriband rivals beat Nutriband on 9 of the 13 factors compared.

Nutriband Company Profile

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.